Dianthus Therapeutics’ (DNTH) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $36.00 price objective on the stock.

Several other equities analysts also recently weighed in on DNTH. Guggenheim reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $52.14.

Dianthus Therapeutics Trading Down 6.3 %

Shares of DNTH stock opened at $21.90 on Wednesday. Dianthus Therapeutics has a 12-month low of $18.13 and a 12-month high of $33.77. The company has a market cap of $648.17 million, a price-to-earnings ratio of -8.76 and a beta of 1.82. The stock has a 50 day simple moving average of $22.65 and a 200-day simple moving average of $24.94.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. On average, equities analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the business. R Squared Ltd acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $26,000. Quest Partners LLC boosted its holdings in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $35,000. Finally, BNP Paribas Financial Markets acquired a new position in Dianthus Therapeutics in the fourth quarter valued at $59,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.